Compare BJ & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BJ | QGEN |
|---|---|---|
| Founded | 1984 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | 5700 |
| Industry | Department/Specialty Retail Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 10.2B |
| IPO Year | 2018 | 1996 |
| Metric | BJ | QGEN |
|---|---|---|
| Price | $91.79 | $47.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 7 |
| Target Price | ★ $112.14 | $50.68 |
| AVG Volume (30 Days) | ★ 2.5M | 1.2M |
| Earning Date | 11-21-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 3.21% |
| EPS Growth | 4.02 | ★ 331.20 |
| EPS | ★ 4.34 | 1.84 |
| Revenue | ★ $21,160,412,000.00 | $2,070,781,000.00 |
| Revenue This Year | $7.97 | $7.12 |
| Revenue Next Year | $6.41 | $6.13 |
| P/E Ratio | ★ $21.05 | $25.56 |
| Revenue Growth | 2.82 | ★ 5.32 |
| 52 Week Low | $86.68 | $37.63 |
| 52 Week High | $121.10 | $51.88 |
| Indicator | BJ | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 50.13 | 55.46 |
| Support Level | $90.18 | $46.39 |
| Resistance Level | $93.55 | $48.13 |
| Average True Range (ATR) | 2.75 | 0.67 |
| MACD | 0.15 | 0.18 |
| Stochastic Oscillator | 55.84 | 68.53 |
BJ's Wholesale serves as one of the few warehouse club chains in the United States. Its 250 warehouses are primarily located along the East Coast, most prominently in the New England area. Similar to its warehouse club peers, BJ's charges annual membership fees and keeps costs down by operating a "no-frills" store environment. The company limits the use of distribution centers where possible and stores inventory on pallets directly on the sales floor, often in bulk quantities. The company also offers a limited assortment of 7,000 stock-keeping units at its warehouses to achieve greater procurement scale on select items. About 80% of BJ's net sales come from grocery items and general merchandise, with the remaining 20% stemming from gasoline and other ancillary services.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).